IDG Capital and SongQing Capital led a $108m Series B funding round in D3 Bio.

IDG Capital, a private equity and venture capital firm, and SongQing Capital, an early‑stage venture capital firm, led a $108m Series B funding round in D3 Bio, a biotechnology company, with participation from WuXi AppTec Corporate Venture Fund, Temasek, Medicxi Ventures, Hongshan Capital Group, and Matrix Partners China. "The completion of our Series B financing demonstrates the strong confidence our investors place in our vision, scientific approach, business operations, and global development capabilities. This funding enables us to advance our lead program into late-stage clinical trials and further expand our pipeline of innovative therapies designed to benefit patients globally," George Chen, D3 Bio Founder, Chairman, and CEO.